The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.
Belantamab mafodotin (Blenrep, GSK) is an antibody-drug conjugate comprised of a humanized B-cell maturation antigen monoclonal antibody conjugated to the cytotoxic agent auristatin F via a noncleavable linker.
The randomized phase 3 DREAMM-8 included 302 participants who had received at least one prior line of multiple myeloma therapy — including a lenalidomide-containing
